In-vitro and in-vivo inhibition of rat neutral endopeptidase and angiotensin converting enzyme with the vasopeptidase inhibitor gemopatrilat

Journal of Hypertension

Volumn 19, Issue 5, 2001, Pages 941-946

  Hubner, Richard A ^a   Kubota, Eiji ^a   Casley, David J ^a   Johnston, Colin I ^a   Burrell, Louise M ^a  

^a UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

Angiotensin converting enzyme; Gemopatrilat; Neutral endopeptidase; Vasopeptidase inhibitor

Indexed keywords

DIPEPTIDYL CARBOXYPEPTIDASE; GEMOPATRILAT; MEMBRANE METALLOENDOPEPTIDASE; UNCLASSIFIED DRUG; VASOPEPTIDASE INHIBITOR;

ARTICLE; AUTORADIOGRAPHY; CONCENTRATION RESPONSE; DOSE RESPONSE; ENZYME INHIBITION; HYPERTENSION; NONHUMAN; PLASMA RENIN ACTIVITY; PRIORITY JOURNAL; RAT;

EID: 0035003857     PISSN: 02636352     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004872-200105000-00015     Document Type: Article

References (16)

1. 1 Roques BP, Noble F, Dauge V, Fournie-Zaluski M-C, Beaumont A. Neutral endopeptidase 24.11: structure, inhibition, and experimental and clinical pharmacology. Pharmacol Reviews 1993; 45:118-146.
2. 2 Levin ER, Gardner DG, Samson WK. Mechanisms of disease - natriuretic peptides. New Engl J Med 1998; 339:321-328.
3. 3 Burnett JC Jr. Vasopeptidase inhibition: a new concept in blood pressure management. J Hypertens 1999; 17:S37-S43.
4. 4 Farina NK, Johnston CI, Burrell LM. Reversal of cardiac hypertrophy and fibrosis by S21402, a dual inhibitor of neutral endopeptidase and angiotensin converting enzyme in SHRs. J Hypertens 2000; 18:749-755.
5. 5 Tikkanen T, Tikkanen I, Rockell MD, Allen, TJ, Johnston CI, Cooper ME, Burrell LM. Dual inhibition of neutral endopeptidase and angiotensin-converting enzyme in rats with hypertension and diabetes mellitus. Hypertension 1998; 32:778-785.
6. 6 Burrell LM, Droogh J, in't Veld OM, Rockell MD, Farina NK, Johnston CI. Antihypertensive and antihypertrophic effects of omapatrilat in SHR. Am J Hypertens 2000; 13:1110-1116.
7. 7 Burrell LM, Hubner RA, Powell J, Johnston CI. In vivo inhibition of angiotensin converting enzyme and neutral endopeptidase by a vasopeptidase inhibitor, BMS189921. J Hypertens 2000; 18:S93.
8. 8 Burrell LM, Farina N, Risvanis J, Woollard D, Casely D, Johnston CI. Inhibition of neutral endopeptidase, the degradative enzyme for natriuretic peptides, in rat kidney after oral SCH42495. Clin Sci 1997; 93:43-50.
9. 9 Jackson B, Cubela R, Johnston CI. Angiotensin converting enzyme (ACE), characterization by 125I-MK351 A binding studies of plasma and tissue ACE during variation of salt status in rat. J Hypertens 1986; 4:759-765.
10. 10 Johnston CI, Mendelsohn FAO, Casely DJ. Evaluation of renin and angiotensin assays and their clinical applications. Med J Aust 1971; 1:126-128.
11. 11 Burrell LM, Palmer J, Charlton JA, Thomas T, Baylis PH. A new radio-immunoassay for human atrial natriuretic peptide and its physiological validation. J Immunoassay 1990; 11:159-175.
12. 12 Friedland J, Silverstein E. A sensitive fluorimetric assay for serum angiotensin-converting enzyme. Am J Clin Pathol 1976; 66:416-424.
13. 13 Kohzuki M, Johnston CI, Chal SY, Jackson B, Perich R, Paxton D, Mendelsohn FA. Measurement of angiotensin converting enzyme induction and inhibition using quantitative in vitro autoradiography: tissue selective induction after chronic lisinopril treatment. J Hypertens 1991; 9:579-587.
14. 14 Burrell LM, Farina NK, Balding LC, Johnston CI. Beneficial renal and cardiac effects of vasopeptidase inhibition with S21402 in heart failure. Hypertension 2000; 36:1105-1111.
15. 15 Kenny AJ, Stephenson SL. Role of endopeptidase-24.11 (enkephalinase) in the inactivation of atrial natriuretic peptide. FEBS Lett 1988; 232:1-8.
16. 16 Helin K, Tikkanen I, Hohenthal U, Fyhrquist F. Inhibition of either angiotensin-converting enzyme or neutral endopeptidase induces both enzymes. Eur J Pharmacol 1994; 264:135-141.